Tovecimig Demonstrates Statistically Significant Benefit in COMPANION-002 Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. ABBV
2. MU
3. SPCX
4. IBM
5. ACN
6. NVDA
7. PRIM
8. META
9. SPY
10. TSLA

Go back to Tovecimig Demonstrates Statistically Significant Benefit in COMPANION-002 Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer
(NASDAQ: CMPX) Delayed: 2.07 -0.03 (1.43%)
Previous Close $2.10    52 Week High $ 
Open $2.04    52 Week Low $ 
Day High $2.10    P/E N/A 
Day Low $2.04    EPS $ 
Volume 938,834